Peptide Vaccines Against Group A Streptococci


This invention relates to synthetic immunoreactive peptides, which are portions of the M proteins of the most prevalent Group A Streptococcus (GAS) serotypes in the United States. These peptides may be useful in development of a flexible, multivalent GAS vaccine. They can be recognized by M type-specific antibodies and are capable of eliciting functional opsonic antibodies. Additionally, the peptides or isolated antibodies raised in response to the peptides may be useful for GAS diagnostics.

Potential Commercial Applications: Competitive Advantages:
  • Group A streptococci (GAS) vaccine
  • GAS therapeutics and diagnostics
  • Lab tools for exploring GAS
 
  • Easily adaptable to kit form
  • Multivalent vaccine that can be tailored for protection against specific GAS serotypes affecting a particular population


Development Stage:
  • Pre-clinical
  • In vitro data available
  • In vivo data available (animal)


Inventors:

Bernard Beall (CDC)  ➽ more inventions...

George Carlone (CDC)  ➽ more inventions...

Jacquelyn Sampson (CDC)  ➽ more inventions...

Edwin Ades (CDC)  ➽ more inventions...


Intellectual Property:
U.S. Pat: 7,407,664 issued 2008-08-05
U.S. Pat: 7,883,710 issued 2011-02-08
U.S. Pat: 8,420,107 issued 2013-04-16
U.S. Pat: 8,637,050 issued 2014-01-28
US Application No. 60/291,835
US Application No. 13/427,477
US Application No. 13/846,166
Various international patent applications pending or issued

Publications:
Bruner M, et al. PMID 12798606

Licensing Contact:
Karen Surabian, J.D., M.B.A.
Email: karen.surabian@nih.gov
Phone: 301-594-9719

OTT Reference No: E-330-2013/0
Updated: Oct 23, 2013